In contrast, PD1/PDL1 inhibitors disrupt the immunosuppressive effects on anti-tumor T cells, leading to increased T cell proliferation and infiltration into the tumor microenvironment, thereby triggering an anti-tumor response. The gene discussed is CD274; the disease is neoplasm.